Researchers reported a redesigned helper plasmid strategy that boosts AAV vector production by tuning expression of E4orf6 and L4-22/33K. The approach, published in Gene Therapy, targets a key bottleneck in viral-vector manufacturing by optimizing regulatory factor ratios used in helper systems. The work addresses variability that can impact batch consistency, yield, and ultimately downstream manufacturing costs. By improving vector output in preclinical and process contexts, the method could support faster development of AAV-based therapies and reduce scale-up friction. In a field where manufacturing capacity constrains clinical and commercial rollout, incremental process improvements like this can have outsized operational value.